Latest News

Results from the IL2-RAPA ITN018AI study, exploring a novel experimental therapy for type 1 diabetes that boosts parts of the healthy immune system, are reported today in the scientific journal Diabetes. The trial was led by Carla Greenbaum, MD, Diabetes Research Program director at Benaroya Research Institute at Virginia Mason (BRI), and sponsored by the Immune Tolerance Network (ITN), a clinical trial network funded by the National Institutes of Health.  The trial took a unique two-pronged approach to treating Type 1diabetes in newly diagnosed participants. Two drugs were administered in combination. One drug interferes with the immune response that causes Type 1 diabetes while a second drug simultaneously boosted the part of the immune response that usually regulates overactive immune cells.

Detailed below is the fifth and final achievement the Immune Tolerance Network (ITN) recently presented at the Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting, and how this work fits in with the broader pursuit of tolerance in transplantation.

Detailed below is a fourth achievement the Immune Tolerance Network (ITN) recently presented at the Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting, and how this work fits in with the broader pursuit of tolerance in allergy.

Detailed below is a third achievement the Immune Tolerance Network (ITN) recently presented at the Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting, and how this work fits in with the broader pursuit of tolerance in transplantation.

Detailed below is a second achievement the Immune Tolerance Network (ITN) recently presented at the Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting, and how this work fits in with the broader pursuit of tolerance in autoimmunity.

Achieving clinical tolerance in allergy, autoimmunity and solid organ transplantation is a daunting challenge due to the complex and multi-faceted nature of the immune system. Part of the ITN’s mission is to unravel the mechanisms of tolerance to better target future strategies for inducing tolerance, and to disseminate these findings. Towards these ends, the ITN hosted a Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting that highlighted five of the ITN’s recent mechanistic and clinical achievements, and how this work fits in with the broader pursuit of tolerance in allergy, autoimmunity and transplantation.

This is a reminder that the Immune Tolerance Network (ITN) is currently seeking short "Concept Proposals" for novel combination therapy clinical trials designed to induce immune tolerance in allergy and asthma. The ITN is especially interested in the following.

The ACCESS ITN034AI clinical trial for lupus nephritis achieved a milestone by completing enrollment of 137 participants, five months ahead of schedule. ACCESS is a randomized, placebo-controlled research study for participants 16 years of age or older who have been diagnosed with lupus and who have developed complications in their kidneys.

Data from an Immune Tolerance Network (ITN) peanut allergy pilot study will be presented in an oral abstract at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) annual meeting in Geneva, Switzerland on June 16-20, 2012.

The Immune Tolerance Netowork (ITN) is hosting a Member Society Symposium entitled “A View Towards (Immune) Tolerance” on June 20^th, 2012 at the Federation of Clinical Immunology Societies (FOCIS) annual meeting in Vancouver, BC, Canada.